From healthcare research to precision medicine

In Switzerland, around 20 percent of children are affected by atopic eczema, compared to 4-5 percent of adults. The disease burden of AD is considerable, which is also related to the fact that those affected have an increased risk of developing other concomitant diseases in addition to atopic eczema. Itching is an immense stress factor and its relief is an essential treatment goal. The therapeutic armamentarium of systemic active substances has expanded in recent years and numerous potential new targets are currently being researched.